Prof Shahneen Sandhu
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
529 Scholarly works
12 Projects
HIGHLIGHTS
2026
Journal article
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
DOI: 10.1186/s13059-026-04074-22026
Journal article
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience
DOI: 10.1016/j.ejca.2026.1168652026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842022
Research grants (ARC, NHMRC, MRFF)
Improving Outcomes for Men With Advanced Prostate Cancer Through Innovative Clinical Trials and Biomarker Development.
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.0022017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
RECENT SCHOLARLY WORKS
2026
Journal article
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma
DOI: 10.1016/j.annonc.2026.04.0102026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
DOI: 10.1038/s41467-026-74076-y2026
Journal article
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
DOI: 10.1200/jco.2026.44.16_suppl.95692026
Journal article
NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
DOI: 10.1200/jco.2026.44.16_suppl.tps96102026
Journal article
A phase 3 randomized, double-blind, placebo-controlled study of a pasritamig plus best supportive care in metastatic castration-resistant prostate cancer.
DOI: 10.1200/jco.2026.44.16_suppl.tps5136
RECENT PROJECTS
2026
Research grants (other domestic)
Understanding Novel Regulators of Cancer Immunotherapy